Sabine Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X by Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), adding:
“With no significant MFS with enza+ADT in Enzarad, benefit was seen in Prostate Cancer patients with N+/pelvic radiation. Question now: is there a true benefit for these patients + can we define criteria to determine a net clinical benefit?”
Quoting Neeraj Agarwal’s post:
“Fantastic talk by Paul Nguyen at ESMO25, result of Ph3 Enzarad trial. The addition of ENZA to ADT + radiation did not improve MFS in all high-risk localized patients, the primary endpoint. However, node+ on CT/MRI patients derived benefit, like the Stampede trial.”
Follow the latest ESMO 2025 news on OncoDaily.
